Show simple item record

dc.contributor.authorBriassoulis, E. Chen
dc.contributor.authorJudson, Ian Roberten
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorBeale, P.en
dc.contributor.authorWanders, J.en
dc.contributor.authorGroot, Y.en
dc.contributor.authorVeerman, G.en
dc.contributor.authorSchuessler, M.en
dc.contributor.authorNiebch, G.en
dc.contributor.authorSiamopoulos, K. C.en
dc.contributor.authorTzamakou, E.en
dc.contributor.authorRammou, D.en
dc.contributor.authorWolf, L.en
dc.contributor.authorWalker, R.en
dc.contributor.authorHanauske, A. R.en
dc.creatorBriassoulis, E. Chen
dc.creatorJudson, Ian Roberten
dc.creatorPavlidis, Nicholasen
dc.creatorBeale, P.en
dc.creatorWanders, J.en
dc.creatorGroot, Y.en
dc.creatorVeerman, G.en
dc.creatorSchuessler, M.en
dc.creatorNiebch, G.en
dc.creatorSiamopoulos, K. C.en
dc.creatorTzamakou, E.en
dc.creatorRammou, D.en
dc.creatorWolf, L.en
dc.creatorWalker, R.en
dc.creatorHanauske, A. R.en
dc.date.accessioned2018-06-22T09:52:43Z
dc.date.available2018-06-22T09:52:43Z
dc.date.issued2000
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41468
dc.description.abstractPurpose: To determine the maximum-tolerated dose (MTD), the principal toxicities, and the pharmacokinetics of 6-hour infusion of glufosfamide (beta-D-glucosylisophosphoramide mustard; D-19575), a novel alkylating agent with the potential to target the glucose transporter system. Patients and Methods: Twenty-one patients (10 women and 11 men; median age, 56 years) with refractory solid tumors were treated with doses ranging from 800 to 6,000 mg/m2. Glufosfamide was administered every 3 weeks as a two-step (fast/slow) intravenous infusion over a 6-hour period. All patients underwent pharmacokinetic sampling at the first course. Results: The MTD was 6,000 mg/m2. At this dose, two of six patients developed a reversible, dose-limiting renal tubular acidosis and a slight increase in serum creatinine the week after the second and third courses of treatment, respectively, whereas three of six patients experienced short-lived grade 4 neutropenia/leukopenia. Other side effects were generally mild. Pharmacokinetics indicated linearity of area under the time-versus-concentration curve against dose over the dose range studied and a short elimination half-life. There was clear evidence of antitumor activity, with a long-lasting complete response of an advanced pancreatic adenocarcinoma and minor tumor shrinkage of two refractory colon carcinomas and one heavily pretreated breast cancer. Conclusion: The principal toxicity of 6-hour infusion of glufosfamide is reversible renal tubular acidosis, the MTD is 6,000 mg/m2, and the recommended phase II dose is 4,500 mg/m2. Close monitoring of serum potassium and creatinine levels is suggested for patients receiving glufosfamide for early detection of possible renal toxicity. Evidence of antitumor activity in resistant carcinomas warrants further clinical exploration of glufosfamide in phase II studies. (C) 2000 by American Society of Clinical Oncology.en
dc.language.isoengen
dc.sourceJournal of Clinical Oncologyen
dc.subjectArticleen
dc.subjectAntineoplastic agentsen
dc.subjectHumanen
dc.subjectNeoplasmsen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectFemaleen
dc.subjectMiddle ageden
dc.subjectPriority journalen
dc.subjectClinical trialen
dc.subjectDrug efficacyen
dc.subjectDrug safetyen
dc.subjectAntineoplastic activityen
dc.subjectInfusionsen
dc.subjectIntravenousen
dc.subjectArea under the curveen
dc.subjectDrug administration scheduleen
dc.subjectDose-response relationshipen
dc.subjectDrugen
dc.subjectSolid tumoren
dc.subjectMaleen
dc.subjectUnclassified drugen
dc.subjectHypokalemiaen
dc.subjectPhase 1 clinical trialen
dc.subjectAlkylating agenten
dc.subjectAlkylatingen
dc.subjectBeta dextro glucopyranosyl nen
dc.subjectDrug blood levelen
dc.subjectDrug half lifeen
dc.subjectDrug selectivityen
dc.subjectGlucose transporteren
dc.subjectGlufosfamideen
dc.subjectHypophosphatemiaen
dc.subjectKidney tubule acidosisen
dc.subjectMaximum permissible doseen
dc.subjectMetabolic acidosisen
dc.subjectMonosaccharide transport proteinsen
dc.subjectN' bis(2 chloroethyl)phosphoric acid diamideen
dc.subjectPancreas canceren
dc.subjectPhosphoramide mustardsen
dc.titlePhase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Groupen
dc.typeinfo:eu-repo/semantics/article
dc.description.volume18
dc.description.issue20
dc.description.startingpage3535
dc.description.endingpage3544
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record